Century Therapeutics (NASDAQ:IPSC) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Century Therapeutics (NASDAQ:IPSC) from a sell rating to a hold rating in a research report released on Saturday morning,Wall Street Zen reports.

Other equities research analysts have also issued research reports about the stock. Mizuho assumed coverage on shares of Century Therapeutics in a research note on Wednesday, May 27th. They set an “outperform” rating and a $8.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Century Therapeutics in a research note on Thursday, July 2nd. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $4.75.

Century Therapeutics Price Performance

Shares of IPSC opened at $2.00 on Friday. The business’s 50-day moving average is $2.09 and its 200-day moving average is $2.23. The company has a market capitalization of $362.14 million, a price-to-earnings ratio of -2.15 and a beta of 1.59. Century Therapeutics has a fifty-two week low of $0.43 and a fifty-two week high of $3.04.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.06). Equities research analysts expect that Century Therapeutics will post -0.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Century Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Quadrant Private Wealth Management LLC boosted its stake in shares of Century Therapeutics by 31.0% during the 1st quarter. Quadrant Private Wealth Management LLC now owns 20,022 shares of the company’s stock worth $45,000 after acquiring an additional 4,736 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Century Therapeutics in the 1st quarter worth approximately $29,000. State of Wyoming acquired a new stake in Century Therapeutics in the 2nd quarter worth approximately $82,000. The Manufacturers Life Insurance Company bought a new stake in Century Therapeutics during the second quarter worth approximately $85,000. Finally, Legal & General Group Plc bought a new stake in Century Therapeutics during the second quarter worth approximately $108,000. Institutional investors and hedge funds own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc is a biotechnology company focused on developing allogeneic cell therapies for cancer and other serious diseases. The company uses induced pluripotent stem cell (iPSC) technology, gene editing and cell-engineering methods to create potentially off-the-shelf immune cell therapies designed to recognize and eliminate diseased cells.

Its pipeline has included engineered natural killer (NK) cell and T-cell programs targeting blood cancers. Among its leading programs is CNTY-101, an allogeneic CAR NK cell therapy directed at CD19, a target associated with certain B-cell malignancies.